PureTech Health plc Stock
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123.00 GBX | -0.32% |
|
-1.60% | -1.60% |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| 07-13 | PureTech Health: Celea Therapeutics Kicks Off Late-stage Trial for Idiopathic Pulmonary Fibrosis Drug | MT |
| Market Cap | 399M 351M 326M 299M 563M 38.47B 571M 3.87B 1.51B 18.91B 1.5B 1.47B 65.39B | P/E 2026 * |
-3.59x | P/E 2027 * | -4.29x |
|---|---|---|---|---|---|
| Enterprise Value | 131M 115M 107M 97.83M 184M 12.57B 187M 1.27B 495M 6.18B 490M 479M 21.37B | EV / Sales 2026 * |
18.4x | EV / Sales 2027 * | 11.5x |
| Free-Float |
84.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PureTech Health plc
| 1 day | -0.32% | ||
| 1 week | -1.60% | ||
| Current month | -10.48% | ||
| 1 month | -6.53% | ||
| 3 months | +0.33% | ||
| 6 months | -8.62% | ||
| Current year | -1.60% |
| 1 week | 120 |  | 127.58 |
| 1 month | 115 | | 140.02 |
| Current year | 107.4 | | 143.6 |
| 1 year | 104.71 | | 148 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 410.66 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 15/07/2025 |
Eric Elenko
PSD | President | 53 | 09/04/2024 |
Charles Sherwood
COO | Chief Operating Officer | - | 01/08/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 08/05/2015 |
John LaMattina
BRD | Director/Board Member | 76 | 01/01/2009 |
| Director/Board Member | 73 | 01/10/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 13/03/26 | Buy | Founder | 112,509 | 0.0466% | ||
| 24/09/25 | Buy | Chairman | 65,250 | 0.0272% | ||
| 24/09/25 | Buy | Director | 59,100 | 0.0246% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.32% | -1.60% | -13.74% | -45.58% | 399M | |
| +1.07% | -3.49% | -3.35% | +10.44% | 46.86B | |
| +0.25% | +1.65% | +399.22% | +634.87% | 40.23B | |
| -0.27% | +4.45% | +11.81% | +65.64% | 36.23B | |
| +0.35% | +0.87% | +4.46% | -10.16% | 34.72B | |
| +3.14% | +1.02% | +4.76% | +40.92% | 27.89B | |
| -0.73% | +11.84% | +34.39% | +134.36% | 16.79B | |
| +0.47% | -2.74% | - | - | 16.74B | |
| +0.42% | -5.52% | -3.43% | +9.03% | 13.12B | |
| -2.68% | -2.49% | -11.36% | -33.61% | 12.7B | |
| Average | +0.17% | +0.59% | +46.97% | +89.55% | 24.57B | |
| Weighted average by Cap. | +0.48% | +0.91% | +74.26% | +135.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.1M 6.24M 5.8M 5.32M 10M 684M 10.15M 68.86M 26.9M 336M 26.65M 26.08M 1.16B | 13.47M 11.83M 11M 10.09M 18.96M 1.3B 19.26M 131M 51.03M 638M 50.55M 49.46M 2.2B |
| Net income | -124M -109M -101M -93.02M -175M -11.95B -177M -1.2B -470M -5.88B -466M -456M -20.31B | -96.8M -85.02M -79.07M -72.55M -136M -9.32B -138M -939M -367M -4.58B -363M -356M -15.85B |
| Net Debt | -269M -236M -220M -202M -379M -25.9B -385M -2.61B -1.02B -12.73B -1.01B -988M -44.02B | -244M -215M -200M -183M -344M -23.53B -349M -2.37B -926M -11.57B -917M -898M -40B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | GBX 123.00 | -0.32% | 301,399 |
| 23/07/26 | GBX 123.40 | -0.64% | 400,284 |
| 22/07/26 | GBX 124.20 | -1.58% | 419,889 |
| 21/07/26 | GBX 126.20 | +0.96% | 614,404 |
| 20/07/26 | GBX 125.00 | 0.00% | 362,182 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Select your edition
All financial news and data tailored to specific country editions
